Aztreonam lysine

ApprovedTerminated
0 watching 0 views this week๐Ÿ”ฅ Hot
84
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Bronchiectasis Adult

Conditions

Bronchiectasis Adult

Trial Timeline

Oct 19, 2019 โ†’ Mar 4, 2025

About Aztreonam lysine

Aztreonam lysine is a approved stage product being developed by Gilead Sciences for Bronchiectasis Adult. The current trial status is terminated. This product is registered under clinical trial identifier NCT03696290. Target conditions include Bronchiectasis Adult.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT00989807Pre-clinicalCompleted
NCT03696290ApprovedTerminated

Competing Products

20 competing products in Bronchiectasis Adult

See all competitors
ProductCompanyStageHype Score
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
77
AZD9668 + PlaceboAstraZenecaPhase 2
52
AZD5069 + PlaceboAstraZenecaPhase 2
52
AZD0292AstraZenecaPhase 2
52
TIP + TIP and placebo + PlaceboNovartisPhase 2
52
Ciprofloxacin DPI (BAYQ3939) + PlaceboNovartisPhase 3
77
Placebo to Ciprofloxacin DPI (BAYQ3939)NovartisPre-clinical
23
Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + PlaceboNovartisPhase 3
77
QBW251 + PlaceboNovartisPhase 2
52
Ciprofloxacin (Cipro, BAYQ3939) + PlaceboNovartisPhase 2
52
AZLI + PlaceboGilead SciencesPhase 3
76
AZLIGilead SciencesPhase 2
51
AZLI + PlaceboGilead SciencesPhase 3
76
Itepekimab (SAR440340) + PlaceboSanofiPhase 2
51
CSL787 + PlaceboCSLPhase 1
32
CSL787 + PlaceboCSLPhase 2
51
HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3
74
HSK31858 + placeboHaisco Pharmaceutical GroupPhase 2
49
Group A + Group BBayerPre-clinical
20
BAY85-8501 + PlaceboBayerPhase 2
49